Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

Abstract Background With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. This study primarily aimed to describe the time to treatm...

Full description

Bibliographic Details
Main Authors: Martin Boegemann, Sara Khaksar, Guillaume Bera, Alison Birtle, Catherine Dopchie, Louis-Marie Dourthe, Els Everaert, Martin Hatzinger, Dirko Hercher, Werner Hilgers, Geoffrey Matus, Laura Garcia Alvarez, Laurent Antoni, Martin Lukac, Geneviève Pissart, Paul Robinson, Tony Elliott
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Cancer
Subjects:
Metastatic castration-resistant prostate cancer
Time to treatment failure
Abiraterone acetate
Real-world evidence
Online Access:http://link.springer.com/article/10.1186/s12885-019-5280-6

Internet

http://link.springer.com/article/10.1186/s12885-019-5280-6

Similar Items